JP2017519729A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519729A5
JP2017519729A5 JP2016567425A JP2016567425A JP2017519729A5 JP 2017519729 A5 JP2017519729 A5 JP 2017519729A5 JP 2016567425 A JP2016567425 A JP 2016567425A JP 2016567425 A JP2016567425 A JP 2016567425A JP 2017519729 A5 JP2017519729 A5 JP 2017519729A5
Authority
JP
Japan
Prior art keywords
carboxamide
oxabicyclo
heptane
pyridin
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567425A
Other languages
English (en)
Japanese (ja)
Other versions
JP6479051B2 (ja
JP2017519729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030303 external-priority patent/WO2015175487A1/en
Publication of JP2017519729A publication Critical patent/JP2017519729A/ja
Publication of JP2017519729A5 publication Critical patent/JP2017519729A5/ja
Application granted granted Critical
Publication of JP6479051B2 publication Critical patent/JP6479051B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567425A 2014-05-13 2015-05-12 軟骨形成を誘導するための化合物および組成物 Active JP6479051B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992815P 2014-05-13 2014-05-13
US61/992,815 2014-05-13
PCT/US2015/030303 WO2015175487A1 (en) 2014-05-13 2015-05-12 Compounds and compositions for inducing chondrogenesis

Publications (3)

Publication Number Publication Date
JP2017519729A JP2017519729A (ja) 2017-07-20
JP2017519729A5 true JP2017519729A5 (https=) 2018-06-07
JP6479051B2 JP6479051B2 (ja) 2019-03-06

Family

ID=53284520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567425A Active JP6479051B2 (ja) 2014-05-13 2015-05-12 軟骨形成を誘導するための化合物および組成物

Country Status (39)

Country Link
US (6) US9688689B2 (https=)
EP (2) EP3143026B1 (https=)
JP (1) JP6479051B2 (https=)
KR (1) KR102375396B1 (https=)
CN (1) CN106459076B (https=)
AP (1) AP2016009502A0 (https=)
AR (1) AR100418A1 (https=)
AU (1) AU2015259403B2 (https=)
BR (1) BR112016025659B1 (https=)
CA (1) CA2947031C (https=)
CL (1) CL2016002838A1 (https=)
CR (1) CR20160528A (https=)
CU (1) CU24392B1 (https=)
DK (1) DK3143026T3 (https=)
EA (1) EA031609B1 (https=)
ES (1) ES2987439T3 (https=)
FI (1) FI3143026T3 (https=)
HR (1) HRP20241236T1 (https=)
HU (1) HUE067954T2 (https=)
IL (1) IL248400B (https=)
JO (1) JO3563B1 (https=)
LT (1) LT3143026T (https=)
MA (1) MA39972B1 (https=)
MX (1) MX377796B (https=)
MY (1) MY186570A (https=)
NZ (1) NZ725044A (https=)
PE (1) PE20161432A1 (https=)
PH (1) PH12016502005B1 (https=)
PL (1) PL3143026T3 (https=)
PT (1) PT3143026T (https=)
RS (1) RS66122B1 (https=)
SG (1) SG11201608823RA (https=)
SI (1) SI3143026T1 (https=)
SV (1) SV2016005316A (https=)
TN (1) TN2016000441A1 (https=)
TW (1) TWI662039B (https=)
UY (1) UY36118A (https=)
WO (1) WO2015175487A1 (https=)
ZA (1) ZA201606929B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2900815T3 (es) 2013-03-15 2022-03-18 Scripps Research Inst Compuestos y métodos para inducir la condrogénesis
EP3143026B1 (en) * 2014-05-13 2024-07-10 Novartis AG Compounds and compositions for inducing chondrogenesis
CN109963579A (zh) * 2016-11-14 2019-07-02 诺华股份有限公司 用于治疗软骨损伤和关节炎的方法和组合物
AU2018257769A1 (en) * 2017-04-24 2019-11-07 The Scripps Research Institute Methods for inducing chondrogenesis
UY37759A (es) * 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis
EP3706710B1 (en) * 2017-11-10 2024-04-10 Novartis AG Extended release formulations for intra-articular applications
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
ES2965684T3 (es) * 2018-12-06 2024-04-16 Novartis Ag Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
CN113015735B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
CN111601789A (zh) * 2018-12-20 2020-08-28 江苏凯迪恩医药科技有限公司 一种含氮杂环化合物、其制备方法及应用
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
RU2733472C1 (ru) * 2020-02-26 2020-10-01 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) N-Ацилгидразон фенхона с фрагментом эпоксиизоиндола, используемый в качестве ингибитора репродукции вируса Хантаан
CN114763347B (zh) * 2021-01-15 2024-06-21 华东师范大学 一类用于诱导间充质干细胞向软骨分化的化合物及其应用
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1443975A (en) 1972-11-02 1976-07-28 Sumitomo Chemical Co Anti-fungal treatment
US3925554A (en) 1972-11-30 1975-12-09 Sumitomo Chemical Co Certain 3,5-dichlorophenyl compound used as a plant fungicide
US4687865A (en) 1986-06-04 1987-08-18 E. R. Squibb & Sons, Inc. Process for preparing 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists
US4707494A (en) 1986-08-26 1987-11-17 E. R. Squibb & Sons, Inc. 7-oxabicyclo(2.2.1)heptane compounds useful in the treatment of inflammation
JP2984077B2 (ja) 1990-04-19 1999-11-29 塩野義製薬株式会社 スルホニルアミノ置換ビシクロ環系ヒドロキサム酸誘導体
US5126370A (en) 1990-12-24 1992-06-30 E. R. Squibb & Sons, Inc. Anti-thrombotic heterocyclic amido prostaglandin analogs
JPH04275182A (ja) 1991-03-01 1992-09-30 Sankyo Kagaku Kk 感熱転写記録用色素
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
HUT74949A (en) 1993-09-10 1997-03-28 Cytomed Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5416106A (en) 1993-12-28 1995-05-16 Allergan, Inc. 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof
US6017953A (en) 1993-12-28 2000-01-25 Allergan Sales, Inc. Thromboxane ligands
FR2718136B1 (fr) 1994-03-29 1996-06-21 Sanofi Sa Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
CA2252918A1 (en) 1996-05-02 1997-11-06 Merck & Co., Inc. Hiv protease inhibitors useful for the treatment of aids
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
GB9908021D0 (en) * 1999-04-08 1999-06-02 Lilly Co Eli Pharmaceutical compounds
WO2000066577A2 (en) 1999-04-29 2000-11-09 Allergan Sales, Inc. Brigded cycloalkanes as thromboxane ligands without blood clotting effects
DE60015392D1 (de) 1999-12-29 2004-12-02 Glaxo Group Ltd Verwendung von annexin-modulatoren zur herstellung eines medikaments zur behandlung und/oder vorbeugung von arthritis und arthritischen erkrankungen
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
CN1213050C (zh) * 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物,其制备方法和作为农药的用途
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
IL157412A0 (en) 2001-02-16 2004-03-28 Aventis Pharmaceuticals Inc Av Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2475773A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
NZ541828A (en) 2003-03-04 2008-06-30 Pfizer Prod Inc Use of EP2 selective receptor agonists in medical treatment
EP2422814A1 (en) 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
JP2005097195A (ja) 2003-09-25 2005-04-14 Institute Of Physical & Chemical Research 医薬組成物
EP1680464A1 (en) 2003-11-07 2006-07-19 Milliken & Company Concentrates of saturated bicyclic dicarboxylate salts as polymer nucleation additives and methods of nucleating thermoplastics
ES2403937T3 (es) 2003-11-13 2013-05-22 Isis Pharmaceuticals, Inc. Derivados de 5,6-dihidroxi-isoindol como conectores para la síntesis de oligómeros en fase sólida
US20050203086A1 (en) 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
EP1792622A1 (en) * 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
WO2007058156A1 (ja) 2005-11-15 2007-05-24 Mitsubishi Chemical Corporation テトラカルボン酸系化合物及びそのポリイミド、ならびにその製造方法
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US7566797B2 (en) 2006-03-03 2009-07-28 Milliken & Company Metal carboxylate salt nucleating or clarifying agent compounds and related polymer compositions and methods
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
JP4275182B2 (ja) 2007-11-02 2009-06-10 シャープ株式会社 熱交換器
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010014141A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
AU2009279936A1 (en) * 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
WO2010099573A1 (en) 2009-03-03 2010-09-10 Deakin University Dioxolane norbornane / norbornene compounds suitable as antimicrobial agents to treat bacterial infections
US20100256385A1 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
PL2432760T3 (pl) 2009-05-18 2013-12-31 Actelion Pharmaceuticals Ltd Pochodne zmostkowanego spiro[2.4]heptanu jako agoniści receptora alx i/lub fprl2
AU2010273570B2 (en) 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
CN101628951B (zh) * 2009-08-12 2011-06-22 中国石油天然气股份有限公司 烯烃聚合用固体催化组分及其催化剂
JP5478161B2 (ja) 2009-09-03 2014-04-23 株式会社クラレ アクリル酸エステル誘導体およびアルコール誘導体並びにそれらの製造方法
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
US8754059B2 (en) 2010-02-16 2014-06-17 University Of Miami Use of miR-30e to treat vascular lesions
CA2803920A1 (en) 2010-06-24 2011-12-29 Richard Beard Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CN103221392B (zh) 2010-11-17 2015-06-03 埃科特莱茵药品有限公司 桥联螺[2.4]庚酯衍生物
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US20140235649A1 (en) 2011-05-24 2014-08-21 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CA2871334A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
EP2867239A4 (en) 2012-06-29 2015-12-23 Lixte Biotechnology Inc OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
JP6262225B2 (ja) 2012-06-29 2018-01-17 リクスト・バイオテクノロジー,インコーポレイテッド オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
RU2016105310A (ru) 2013-07-18 2017-08-23 Актелион Фармасьютиклз Лтд Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора
EP3143026B1 (en) * 2014-05-13 2024-07-10 Novartis AG Compounds and compositions for inducing chondrogenesis

Similar Documents

Publication Publication Date Title
JP2017519729A5 (https=)
HRP20241236T1 (hr) Spojevi i pripravci za induciranje hondrogeneze
US8685993B2 (en) Bi-heteroaryl compounds as Vps34 inhibitors
US7820817B2 (en) Modulators of muscarinic receptors
CA2845578C (en) Pyrimidine pde10 inhibitors
CA2984259A1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
JP6175673B2 (ja) Ttx−s遮断薬としてのアミド誘導体
EP2739616A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
SA520411465B1 (ar) مركبات فعّالة علاجياً وطرق استخدامها
EP3661560A1 (en) Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
BRPI0720270A2 (pt) Compostos basedos em 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina e processos de usos dos mesmos
JP2010508338A5 (https=)
AR069206A1 (es) Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros.
JP2016519096A5 (https=)
RU2010116352A (ru) Производные 1,1,1-трифтор-2-гидрокси-3-фенилпропана
JP2019532911A (ja) Nav1.7およびNav1.8遮断薬としてのアミド誘導体
TW201546070A (zh) 4-氮雜吲哚衍生物
IL205501A (en) Preparation of preparations for the treatment of arthritis
EP3849664A1 (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
EP3585365A1 (en) Combination of atr kinase inhibitors with parp inhibitors
EP3856736A1 (en) Novel compounds as nadph oxidase inhibitors
JP2021521178A (ja) Pi3キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体
TW201216966A (en) Combinations comprising DHODH inhibitors and COX inhibitors
JP2026504481A (ja) ジアシルグリセロールキナーゼ(dgk)阻害剤の組合せ
TW202602875A (zh) Stat6降解劑